New generation antidepressants for depression in children and adolescents: a network meta-analysis-Reference-Cited by-同舟云学术

New generation antidepressants for depression in children and adolescents: a network meta-analysis

Published:2021-05-24 Issue:5 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Hetrick Sarah E¹²,McKenzie Joanne E³,Bailey Alan P⁴⁵,Sharma Vartika¹²,Moller Carl I⁴⁵,Badcock Paul B⁴⁵⁶,Cox Georgina R⁷,Merry Sally N⁸,Meader Nicholas⁹¹⁰

Affiliation:

1. Department of Psychological Medicine, Faculty of Medical and Health Sciences; The University of Auckland; Auckland New Zealand

2. Children and Young People Satellite, Cochrane Common Mental Disorders; The University of Auckland; Auckland New Zealand

3. School of Public Health and Preventive Medicine; Monash University; Melbourne Australia

4. Orygen; Parkville Australia

5. Centre for Youth Mental Health; The University of Melbourne; Parkville Australia

6. Melbourne School of Psychological Sciences; The University of Melbourne; Victoria Australia

7. Department of Paediatrics; Monash University; Melbourne Australia

8. Department of Psychological Medicine; University of Auckland; Auckland New Zealand

9. Centre for Reviews and Dissemination; University of York; York UK

10. Cochrane Common Mental Disorders; University of York; York UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference273 articles.

1. Treatment of major depressive disorder with fluoxetine in children and adolescents. A double-blind, placebo-controlled study;Almeida-Montes;Psiquiatria Biologica,2005

2. A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder;Atkinson;Journal of Child and Adolescent Psychopharmacology,2014

3. High rate of non-eligibility: methodological factors impacting on recruitment for a multicentre, double-blind study of paediatric patients with major depressive disorder;Bliznak;Pharmacopsychiatry,2013

4. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder;Emslie;Journal of Child and Adolescent Psychopharmacology,2015

5. A double-blind, efficacy and safety study of duloxetine versus placebo in the treatment of children and adolescents with major depressive disorder clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-006492-71

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic bioactivation of antidepressants: advance and underlying hepatotoxicity;Drug Metabolism Reviews;2024-02-04

2. Use of nitrous oxide in the treatment of major depressive disorder and treatment-resistant major depressive disorder: A systematic review and meta-analysis nitrous oxide in depressive disorders;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2024-02

3. Electroconvulsive therapy for adolescents with severe depressive episode and suicidality: retrospective comparison between responders and non-responders;Child and Adolescent Psychiatry and Mental Health;2024-01-20

4. A Delphi consensus among experts on assessment and treatment of disruptive mood dysregulation disorder;Frontiers in Psychiatry;2024-01-08

5. Influencia del uso de medicamentos psicotrópicos en el aumento de resistencia Escherichia coli;Salud, Ciencia y Tecnología;2023-12-27